When should a GLP‑1 receptor agonist be started and at what dose in an adult with type 2 diabetes needing additional glucose lowering and weight loss, without personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, and who can tolerate subcutaneous injections?

GLP-1 Receptor Agonist Initiation in Type 2 Diabetes

Start a GLP-1 receptor agonist immediately when additional glucose lowering and weight loss are needed in an adult with type 2 diabetes who can tolerate subcutaneous injections and has no contraindications. GLP-1 RAs are now the preferred first injectable therapy over insulin for most patients with type 2 diabetes 1, 2.

When to Start

Initiate a GLP-1 RA in the following scenarios:

• Metformin alone is insufficient to achieve individualized A1C targets 3
• Weight loss is a treatment goal alongside glucose lowering 2, 4
• Established cardiovascular disease (CVD) is present - GLP-1 RAs with proven CV benefit (liraglutide, semaglutide, dulaglutide) should be started independent of A1C level or glucose-lowering needs 5, 3, 6
• High cardiovascular risk exists (age ≥55 with coronary/carotid/peripheral artery stenosis >50%, left ventricular hypertrophy, eGFR <60, or albuminuria) 6
• Advanced chronic kidney disease (eGFR <30 mL/min/1.73 m²) where SGLT2 inhibitors have reduced efficacy 2
• A1C ≥7.5% at diagnosis - consider early combination therapy with metformin plus GLP-1 RA 3

Which GLP-1 RA and Starting Dose

Prioritize semaglutide for maximum efficacy in glucose lowering (A1C reduction ~1.5-2%) and weight loss (14-16% body weight reduction) 7, 4, 8.

Semaglutide Dosing:

• Subcutaneous: Start 0.25 mg once weekly for 4 weeks, then increase to 0.5 mg weekly. If additional control needed, increase to 1 mg weekly after another 4 weeks 7
• Oral: Start 3 mg once daily (taken 30 minutes before first food/fluid with ≤120 mL plain water), increase to 7 mg after 30 days, then 14 mg if needed 7

Alternative Options:

Liraglutide (if daily injection preferred or cost considerations):

• Start 0.6 mg daily for 1 week, increase to 1.2 mg daily, can titrate to 1.8 mg daily 7
• Has proven CV benefit in patients with established CVD 5, 9

Dulaglutide (once-weekly alternative):

• Start 0.75 mg once weekly, increase to 1.5 mg weekly if needed 7
• Has proven CV benefit 5

Lixisenatide or exenatide (lower cost options):

• Lixisenatide: 10 mcg daily for 14 days, then 20 mg daily 7
• Exenatide: 5 mcg twice daily for 1 month, then 10 mcg twice daily 7
• Note: These have less robust CV outcome data 8

Critical Dosing Strategy

Always start at the lowest dose and titrate slowly to minimize gastrointestinal side effects (nausea, vomiting, diarrhea), which are the primary reason for discontinuation 5, 10. The gradual titration is essential - rushing this process significantly increases treatment discontinuation rates 10.

Practical Considerations

Timing of administration:

• Once-weekly agents (semaglutide, dulaglutide, exenatide XR) can be given any time of day, any day of week 7, 11
• Daily agents (liraglutide) can be given any time of day 7
• Twice-daily exenatide should be given within 60 minutes before morning and evening meals 7
• Lixisenatide should be given within 60 minutes before first meal 7

Combination with other medications:

• Continue metformin when adding GLP-1 RA 3
• If on sulfonylureas or insulin, reduce those doses by 10-20% to prevent hypoglycemia 5, 1
• GLP-1 RAs can be combined with SGLT2 inhibitors for additive cardiorenal benefits 12
• Fixed-ratio combinations (basal insulin + GLP-1 RA) are available if both are needed 1, 9

Monitoring and Adjustment

Reassess at 3-4 months:

• If A1C not at goal, uptitrate GLP-1 RA dose before adding other agents 3
• If gastrointestinal symptoms persist beyond initial weeks, consider switching to a different GLP-1 RA or slowing titration 5, 10
• Monitor for weight loss - expect 5-15% body weight reduction depending on agent 4, 8

Common Pitfalls to Avoid

Do not delay GLP-1 RA initiation in favor of adding multiple oral agents - GLP-1 RAs are more effective and provide CV/renal benefits that oral agents (except SGLT2 inhibitors) do not 1, 2.

Do not start with insulin instead of GLP-1 RA unless there is evidence of catabolism (unexpected weight loss), severe hyperglycemia symptoms, A1C >10%, or glucose ≥300 mg/dL [1,2, @23@].

Do not discontinue prematurely due to early gastrointestinal symptoms - these typically resolve within 2-4 weeks 5, 10. Counsel patients upfront about expected transient nausea.

Do not forget to reduce insulin/sulfonylurea doses when adding GLP-1 RA to prevent hypoglycemia 5, 1.

Renal Dosing

No dose adjustment needed for any GLP-1 RA except:

• Exenatide: not recommended if CrCl <30, use caution if CrCl 30-50 7
• Lixisenatide: not recommended if CrCl <15 7
• All others (semaglutide, liraglutide, dulaglutide): no adjustment required at any level of renal function 7